The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis
Abstract
Purpose To determine the effect of prednisone dose and hydroxychloroquine dose on the coronary artery disease risk factors serum cholesterol level, mean arterial blood pressure, and weight in patients with systemic lupus erythematosus.Patients and methods A longitudinal cohort study of 264 patients with systemic lupus erythematosus was conducted. For all patients in the cohort, serum cholesterol, mean arterial pressure, weight, prednisone dose, hydroxychloroquine dose, and other potential confounding variables were recorded at each visit. Regression analysis appropriate for longitudinal data was used to assess the effect of prednisone on serum cholesterol and mean arterial pressure. To assess the effect of prednisone on weight, patients' weights were compared 90 days before and after a 10-mg or 20-mg increase in prednisone.Results A total of 3,027 patient visits were analyzed. In the regression model for serum cholesterol, a change in prednisone dose of 10 mg was associated with a change in cholesterol of 7.5 +/- 1.46 (SE) mg% after adjustment for the other significant variables in the model, including sex, race, hydroxychloroquine dose, and proteinuria. In the regression model for hydroxychloroquine, the 200-mg and the 400-mg dose were both associated with lower serum cholesterol (8.9 +/- 3.44 SE mg%). In the regression model for mean arterial blood pressure, a 10-mg change in prednisone dose led to a change in mean arterial blood pressure of 1.1 mm Hg after adjustment for age, weight, and antihypertensive drug use. A 10-mg increase in prednisone dose was associated with a mean weight change of 5.50 +/- 1.23 (SE) lb.Conclusions Changes in prednisone dose led to definable changes in risk factors for coronary artery disease, even after adjustment for other variables known to affect these risk factors. According to longitudinal regression analysis, hydroxychloroquine therapy was associated with lower serum cholesterol.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple retrospective and a few prospective studies (3–13) have found that hydroxychloroquine (HCQ) reduces the risk of arterial and venous thrombosis.”
From Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus (2021) · cites this paper as [5]
Citations
Cites
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,781
The Lipid Research Clinics Coronary Primary Prevention Trial Results
(1984) · JAMA · doi:10.1001/jama.1984.03340270043026 · Cited by 1,404
The bimodal mortality pattern of systemic lupus erythematosus
Urowitz, M. B., BOOKMAN, A. A. M., Koehler, B. E., Gordon, D. A., SMYTHE, H. A., & Ogryzlo, M. A. (1976) · The American Journal of Medicine · doi:10.1016/0002-9343(76)90431-9 · Cited by 999
Lipid Research Clinics Program
Renfrew, R. A. (1984) · JAMA · doi:10.1001/jama.1984.03350180015009 · Cited by 829
The Effects of Nonpharmacologic Interventions on Blood Pressure of Persons With High Normal Levels
Whelton, P. K. (1992) · JAMA · doi:10.1001/jama.1992.03480090061028 · Cited by 768
The Canadian Hydroxychloroquine Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199101173240303 · Cited by 676
The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy
Bulkley, B. H., & Roberts, W. C. (1975) · The American Journal of Medicine · doi:10.1016/0002-9343(75)90575-6 · Cited by 672
Risk factors for coronary artery disease in patients with systemic lupus erythematosus
Petri, M., Perez‐Gutthann, S., Spence, D., & Hochberg, M. C. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90578-y · Cited by 623
Self-citation
Research works printed but not linked: 2
- Cumming, 1989, Cardiovascular disease-related knowledge and attitudes in a high-risk Australian population, Med J Aust, 150, 556, 10.5694/j.1326-5377.1989.tb136692.x · DOI
- Bush, 1988, Cholesterol, lipoproteins, and coronary heart disease in woman, Clin Chem, 34, B60
Cited by
Sorted by citations
Items 201–300 of 323
Lang, M. G., Vinagre, C. G. C., Bonfá, E., Freitas, F. R., Pasoto, S. G., Brito, T. S., Seguro, L. P. C., Maranhão, R. C., & Borba, E. F. (2022) · Lupus · doi:10.1177/09612033221090127 · Cited by 12
The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus
Siripaitoon, B., Osiri, M., Vongthavaravat, V., Akkasilpa, S., & Deesomchok, U. (2004) · Lupus · doi:10.1191/0961203304lu1084xx · Cited by 10
Castrejón, I., Nika, A., Sequeira, W., & Jolly, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-59963-2_6 · Cited by 10
Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice
Petri, M. (2011) · International Journal of Rheumatic Diseases · doi:10.1111/j.1756-185x.2010.01590.x · Cited by 9
Self-citationFischer, K. M., & Brzosko, M. (2009) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.827 · Cited by 9
Lorenzis, E. D., Gremese, E., Bosello, S. L., Nurmohamed, M. T., Sinagra, G., & Ferraccioli, G. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.02.002 · Cited by 9
Cœur et anticorps antiphospholipides Expérience personnelle et revue de la littérature
Blétry, O., Wechsler, B., Pietté, J. C., de Zuttere, D., & Godeau, P. (1996) · La Revue de Médecine Interne · doi:10.1016/0248-8663(96)88395-0 · Cited by 9
Antimalarials in systemic lupus erythematosus: benefits beyond disease activity
Andrade, R. M., & Alarcón, G. S. (2006) · Future Rheumatology · doi:10.2217/17460816.1.2.225 · Cited by 9
Accelerated atherosclerosis and inflammation in systemic lupus erythematosus
Asanuma, Y. (2012) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.35.470 · Cited by 8
Accelerated atherosclerosis and cardiovascular disease in systemic lupus erythematosus
Quintana, R., Pons‐Estel, G., Serrano, R., Pons‐Estel, B. A., & Bruce, I. N. (2021) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2021.03.002 · Cited by 8
Atherosclerosis in Systemic Lupus Erythematosus
Jiménez, S., Ramos‐Casals, M., Cervera, R., Font, J., & Ingelmo, M. (2001) · Elsevier eBooks · doi:10.1016/b978-044450669-6/50029-3 · Cited by 8
Drug monitoring in systemic lupus erythematosus
Petri, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102225 · Cited by 8
Self-citationFriedrich, C. A., & Rader, D. J. (1999) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70084-3 · Cited by 7
The second hit: comorbidities in systemic lupus erythematosus
Pineau, C. A., Lee, C., Ramsey‐Goldman, R., Clarke, A. E., & Bernatsky, S. (2007) · Future Rheumatology · doi:10.2217/17460816.2.5.497 · Cited by 6
Prevention of cardiovascular disease in patients with rheumatic diseases
Domsic, R. T., Maksimowicz‐McKinnon, K., & Manzi, S. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.04.005 · Cited by 6
Feldt, J. M. V., Eisner, E. R., & Sawaires, A. (2002) · JCR Journal of Clinical Rheumatology · doi:10.1097/00124743-200212000-00006 · Cited by 6
Assessment of Coronary Risk Based on Cumulative Exposure to Lipids in Systemic Lupus Erythematosus
Nikpour, M., Gladman, D. D., Ibañez, D., Harvey, P., & Urowitz, M. B. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.121273 · Cited by 6
Dakua, S., Behera, M., Panda, J. K., & Padhi, P. K. (2017) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20174667 · Cited by 6
Cardiovascular Morbidity in the Hopkins Lupus Cohort
Petri, M. (2001) · Elsevier eBooks · doi:10.1016/b978-044450669-6/50028-1 · Cited by 6
Self-citationLevinson, D. J., Abugroun, A., & Osinski, K. I. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100089 · Cited by 5
Type-5 Cardiorenal Syndrome (CRS-5): An up to Date
Lullo, L. D., Ronco, C., Cozzolino, M. G., Selvi, A., Santoboni, F., & Bellasi, A. (2017) · Nephrology Point of Care · doi:10.5301/napoc.5000212 · Cited by 5
Systemic Lupus Erythematosus for Primary Care
Kado, R. (2018) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2018.02.011 · Cited by 5
Laboratory Features of Cutaneous Lupus Erythematosus
Shinada, S., & Wallace, D. J. (2005) · Springer eBooks · doi:10.1007/3-540-26581-3_23 · Cited by 5
Cardiac Involvement in Systemic Lupus Erythematosus
Doria, A., & Petri, M. (2003) · Technical report · doi:10.1016/s1571-5078(03)01010-9 · Cited by 5
Self-citationClinical, pharmacokinetic and technological aspects of the hydroxychloroquine sulfate
Ferraz, L. R. D. M., Santos, F. L. A., Ferreira, P. D. A., Maia, R. T. L., Rosa, T. A., Rolim, L. A., & Neto, P. J. R. (2014) · IOSR Journal of Pharmacy (IOSRPHR) · doi:10.9790/3013-04011053064 · Cited by 5
Callen, J. P., & Camisa, C. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-2003-7.00019-4 · Cited by 4
Manifestations cardiaques des maladies auto-immunes et vascularites
Chapelon-Abric, C. (2016) · Cited by 4
Faut-il doser l'hydroxychloroquine chez les patients lupiques ?
Costedoat-Chalumeau, N., Amoura, Z., Hulot, J., Lechat, P. P., & Pietté, J. C. (2006) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2006.05.002 · Cited by 4
Corticosteroid and Nonsteroidal Anti-Inflammatory Drug use in Systemic Lupus Erythematosus
Dvorkina, O., & Ginzler, E. M. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10056-7 · Cited by 4
Komaki, T., Miura, S.-I., Gondo, K., Nakamura, A., Ike, A., Matsunaga, A., & Saku, K. (2017) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2017.04.008 · Cited by 4
Refining lupus management: a comprehensive review of HCQ blood levels
Saleh, Z., & Kahlenberg, J. M. (2025) · Rheumatology Advances in Practice · doi:10.1093/rap/rkaf080 · Cited by 3
Checa, C. M., Salvatierra, J., Rosales-Alexander, J. L., & Álvarez, E. R. (2012) · Seminarios de la Fundación Española de Reumatología · doi:10.1016/j.semreu.2012.06.004 · Cited by 3
Akiash, N., Abbaspour, S., Mowla, K., Moradi, A., Madjidi, S., Sharifi, P., & Pazoki, M. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00511-4 · Cited by 5
Park, S., Hwang, H. Y., Kang, H., & Kim, K. (2011) · The Korean Journal of Thoracic and Cardiovascular Surgery · doi:10.5090/kjtcs.2011.44.6.423 · Cited by 3
Fischer‐Betz, R., Beer, S., & Schneider, M. (2005) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-005-0733-5 · Cited by 3
Cardiovascular Involvement in Systemic Lupus Erythematosus
Abdulaziz, S., Al-Ghamdi, Y., Samannodi, M. S., & Shabrawishi, M. (2012) · InTech eBooks · doi:10.5772/37351 · Cited by 3
CARDIOVASCULAR SYSTEMIC LUPUS ERYTHEMATOSUS
Petri, M. (2004) · Elsevier eBooks · doi:10.1016/b9-78-012433-9/01950-034x · Cited by 3
Self-citationLupus eritematoso sistémico y enfermedad cardiovascular
Jiménez, S., Font, J., & Ingelmo, M. (2002) · Medicina Clínica · doi:10.1016/s0025-7753(02)73546-x · Cited by 3
Costedoat-Chalumeau, N., Leroux, G., Pietté, J. C., & Amoura, Z. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10057-9 · Cited by 3
Jain, A., Livnat, I., Tsipursky, M. S., Almasov, A., Garwood, K. C., & Labriola, L. T. (2019) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126419836067 · Cited by 3
Callen, J. P., Rosenbach, M. A., & Camisa, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-61211-1.00021-8 · Cited by 3
Phuong, T. N. T., Thi, T. D., Lundberg, I. E., & Huy, B. N. (2022) · Rheumatology Advances in Practice · doi:10.1093/rap/rkac048 · Cited by 3
Therapy of cutaneous lupus erythematosus
Clarke, J. T., & Werth, V. P. (2006) · Expert Review of Dermatology · doi:10.1586/17469872.1.1.105 · Cited by 3
Antirheumatic drugs and cardiovascular disease in rheumatoid arthritis
Szekanecz, Z., Szűcs, G., & Kerekes, G. (2023) · Rheumatology Forum · doi:10.5603/rf.2023.0010 · Cited by 2
Tam, L., Li, E. K., & Tomlinson, B. (2006) · Hong Kong Journal of Nephrology · doi:10.1016/s1561-5413(09)60232-5 · Cited by 2
Athérosclérose et connectivites
Meyer, O. (2001) · Revue du Rhumatisme · doi:10.1016/s1169-8330(01)00210-1 · Cited by 2
The influence of other drugs on coronary heart disease (CHD) risk in systemic lupus erythematosus
Bruce, I. N. (2006) · Lupus · doi:10.1177/0961203306071674 · Cited by 2
A new role for antimalarials in systemic lupus erythematosus treatment
Ayensa, J.-L., Khamashta, M. A., & Ruiz‐Irastorza, G. (2010) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.10.25 · Cited by 2
Kumar, B., Pannu, S., & Akhtar, M. J. (2021) · Current Pharmaceutical Analysis · doi:10.2174/1573412917666210625123509 · Cited by 2
Wang, S., Li, W., Li, T.-F., Xu, L., Yan, Y.-L., & Liu, S. (2022) · PubMed Central · Cited by 2
Standard therapeutic regimens for vasculitis
Tervaert, J. W. C., Stegeman, C. A., & Kallenberg, C. G. M. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8235-4_2 · Cited by 2
Hydroxychloroquine in Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al
Michaud, M., & Gaches, F. (2015) · Arthritis Care & Research · doi:10.1002/acr.22780 · Cited by 2
ANTIMALARIALS AND IMMUNOSUPPRESSIVE THERAPIES
DAVIS, J., & KLIPPEL, J. (2004) · Elsevier eBooks · doi:10.1016/b9-78-012433-9/01950-0508 · Cited by 2
Han, D.-L., Li, L., Shi, J., Ge, Y., Yang, S.-L., Chu, Y., Mai, Z.-Y., Zhang, Y. L., Chen, H., Jing, Y., et al. (2026) · Trials · doi:10.1186/s13063-026-09470-4 · Cited by 1
Carvalho, L. M., da Mota, J. C. N. L., Ribeiro, A., Souza, L., Sales, R., Gualano, B., Martínez‐Urbistondo, M., Martínez, J. A., Borba, E. F., & Nicoletti, C. F. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s579501 · Cited by 1
Pharmacotherapy in Systemic Lupus Erythematosus
Borham, L. E. (2012) · Current Rheumatology Reviews · doi:10.2174/157339710803140210193833 · Cited by 1
Cardiac involvement in systemic lupus erythematosus
Wisłowska, M. (2008) · Annales UMCS Medicina · doi:10.2478/v10079-008-0003-5 · Cited by 1
CME CVD in SLE Accelerated cardiovascular disease in patients with lupus: A review
Seavy, L. M., & Grosel, J. M. (2012) · JAAPA · doi:10.1097/01720610-201212000-00006 · Cited by 1
Anti-Inflammatory Therapeutic Approaches
Szekanecz, Z., Kerekes, G., & Shoenfeld, Y. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0338-8_26 · Cited by 1
Cardiac Involvement in Systemic Lupus Erythematosus
Iaccarino, L., Gatto, M., Zen, M., & Doria, A. (2017) · Technical report · doi:10.1016/b978-0-12-803997-7.00011-9 · Cited by 1
Alhefny, A. A., Bakry, S. A. E., & Shedid, N. H. (2014) · Egyptian Journal of Rheumatology & Clinical Immunology · doi:10.21608/ejrci.2014.9451 · Cited by 1
Maternal and foetal outcome of pregnancy in women with connective tissue diseases
Klimaszyk, K., Wender-Ożegowska, E., & Kędzia, M. (2021) · Journal of Medical Science · doi:10.20883/medical.e525 · Cited by 1
Association between Abnormal Lipid Levels and Systemic Lupus Erythematosus
Rezaeian, M., Abbasi, A., & Abbasifard, M. (2021) · Rheumatology Research · doi:10.22631/rr.2021.69997.1118 · Cited by 1
Huang, H., Ma, X., Xu, L., Wang, X., Shi, D., Zhao, F., & Zhang, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.951188 · Cited by 1
Hydroxychloroquine, QTc prolongation and risk of torsades de pointes
Subhan, S., Wang, A. Y.-D., Dey, S., Tang, W., & Aronow, W. S. (2023) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/169982 · Cited by 1
Inflammatory Diseases of the Coronary Artery
Shanahan, J. C., & Clair, E. W. S. (2002) · Springer eBooks · doi:10.1007/978-3-642-56225-9_59 · Cited by 1
Is there an Effective Treatment for Late-Onset Systemic Lupus Erythematosus?
Ugarte-Gil, M. F., & Alarcón, G. S. (2013) · Aging Health · doi:10.2217/ahe.13.36 · Cited by 1
Lullo, L. D., & Ronco, C. (2020) · Springer eBooks · doi:10.1007/978-3-030-57460-4_10 · Cited by 1
Silva, L. M. T., Cortes, A., Rossi, B., Boll, L. F. C., Waclawovsky, G., Eibel, B., Gonçalves, S. C., Irigoyen, M. C., & Martinez, D. (2021) · Trials · doi:10.1186/s13063-021-05610-0 · Cited by 2
Impacto de la enfermedad cardiovascular en el síndrome de Sjögren primario
Novo, M. P. D. L. (2010) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · Cited by 1
Studies on cardiovascular risk factors in Systemic Lupus Erythematosus
Gustafsson, J. T. (2012) · Figshare · Cited by 1
Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus?
Wallace, D. J. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0876 · Cited by 1
Lupus eritematoso sistémico y ateromatosis acelerada
Urquizu-Padilla, M., & Ordi‐Ros, J. (2004) · Medicina Clínica · doi:10.1016/s0025-7753(04)75335-x · Cited by 1
Serological Biomarkers in Systemic Lupus Erythematosus
Chan, M. T.-L. (2013) · The University of Bath Online Publications Store (The University of Bath)
ANTIMALARIAL DRUGS IN THERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS: PAST, PRESENT, FUTURE
Lisitsyna, T. A., & Kosheleva, N. M. (2010) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2010-608
Sachet, J. C. (2006) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2006.tde-01112006-224013
Dyslipoproteinemia and Premature Atherosclerosis in the Pediatric Rheumatic Disease
Milojevic, D. S., & Ilowite, N. T. (2001) · Elsevier eBooks · doi:10.1016/b978-044450669-6/50037-2
Lima, J. E., Lozovoy, M. A. B., Alfieri, D. F., Delongui, F., Kallaur, A. P., Reiche, E. M. V., & de Almeida, E. R. D. (2014) · Semina Ciências Biológicas e da Saúde · doi:10.5433/1679-0367.2015v36n1suplp109
Altman, A., & Shoenfeld, Y. (2012) · PubMed
Sella, E. M. C., & Sato, E. I. (2004) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042004000400004
Minowa, K., Morimoto, S., Takasaki, Y., Tamayama, Y., & Tokano, Y. (2010) · Juntendō Igaku/Juntendo igaku · doi:10.14789/pjmj.56.268
What will treatment of autoimmune diseases entail in 2010?
Huizinga, T. W. J., & Breedveld, F. C. (2002) · Springer eBooks · doi:10.1007/978-3-662-04759-0_13
Athérome et lupus érythémateux systémique
Soubrier, M., Mathieu, S., & Dubost, J. (2007) · Revue du Rhumatisme · doi:10.1016/j.rhum.2007.04.006
Atherosclerosis in the Rheumatic Diseases: Compounding the Age Risk
Yokogawa, N., & Feldt, J. M. V. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5792-4_3
Lipid Abnormalities in Children with Systemic Lupus Erythematosus (SLE)
(2006) · AAP Grand Rounds · doi:10.1542/gr.16-4-45
Bjarnegård, N. (2008) · DiVA (Linkoping University)
Actividad del lupus eritematoso sistémico y marcadores sanguíneos asociados a aterosclerosis
Urquizu-Padilla, M. (2008) · TDX (Tesis Doctorals en Xarxa)
Vascular progenitor cells in renal and cardiovascular disease
Westerweel, P. E. (2008) · Utrecht University Repository (Utrecht University)
Artrite Reumatóide e Doenças Cardiovasculares Rheumatoid Arthritis and Cardiovascular Disease
Torigoe, D. Y., & Laurindo, I. M. M. (2006)
Perfil lipídico de pacientes com lupus eritematoso sistêmico em um hospital universitário
Marques, C. D. L. (2003) · Americanae (AECID Library)
Shiruli, B. C. (2014) · African journal of rheumatology
Ogola, E. N., Oyoo, G. O., Aywak, A. A., Shiruli, B., & Amayo, E. O. (2014)
Lu, C., Lai, J., Chen, C., Lee, T. S., Tsai, C., Kuo, S.-Y., & Chang, D.-M. (2011) · Formosan journal of rheumatology · doi:10.6313/fjr.2011.25(1-2).11
Homocysteine and Vascular Disease in the Autoimmune Connective Tissue Diseases
(2001) · CRC Press eBooks · doi:10.1201/9781420040395-13
Cardiovascular Risk and Prevention in Rheumatic Diseases
Husni, M. E., & Khasnis, A. A. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6643-9.00188-0
Cardiac Effects of Antirheumatic Drugs
Szekanecz, Z. (2017) · Technical report · doi:10.1016/b978-0-12-803997-7.00020-x
Cardiac and Vascular Disease in SLE
Sands, R. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1189-5_8
Assessment for Early Cardiovascular Risk in Pediatric Rheumatic Disease
Tyrrell, P. N. (2012) · TSpace (University of Toronto)
Metadata
- Authors
- Petri, M., Lakatta, C., Magder, L., & Goldman, D.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Petri, Michelle
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 1994-03
- Volume
- 96
- Issue
- 3
- Pages
- 254-259
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2021741488
- Cited by
- 323
- References
- 25
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 12 · 2020: 8 · 2019: 6 · 2018: 10 · 2017: 14 · 2016: 6 · 2015: 6 · 2014: 16 · 2013: 15 · 2012: 23
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29hl047080-02)
- National Heart, Lung, and Blood Institute (HL 47080-01)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- systemic lupus erythematosus, prednisone, hydroxychloroquine, coronary risk factors, serum cholesterol, mean arterial pressure, body weight, glucocorticoid dose, hypolipidemic effect
- MeSH terms
- Adult, Blood Pressure, Body Weight, Cholesterol, Coronary Disease, Female, Humans, Hydroxychloroquine, Lupus Erythematosus, Systemic, Male, Middle Aged, Prednisone, Regression Analysis, Risk Factors, Linear Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review